Business Wire

New Custom made by ReSound rechargeable hearing aids: the most advanced technology in a stylish design

Share

GN Hearing, the global leader in hearing aid innovation, today announces the most advanced, rechargeable Custom made by ReSound hearing aids. These hearing aids provide all day use, streaming from iPhone and iPad or AndroidTM smartphones, and comfort with superior sound quality, in a stylish design. Custom made by ReSound hearing aids offer medical-grade, customized, full-time hearing support and care, whereas the recently launched Jabra Enhance Plus is intended for people needing occasional hearing support. GN continues to combine expertise from the hearing and audio worlds with the goal to enable millions of people in taking an important step on their hearing health journey.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005063/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Runner wearing Custom made by ReSound hearing aids (Photo: Business Wire)

According to research, 58% of people try headphones to help with their hearing, before moving onto hearing aids*. Now they can get a stylish, custom made hearing aid with expertise and support from a hearing care professional. Every ear is different, so each Custom made by ReSound hearing aid is meticulously crafted in a series of highly technical, specialized processes. Molded to fit the individuals’ unique ear canal, they can be worn comfortably and confidently all day long.

These new rechargeable hearing aids are the first in the world to come with a customized case containing specially created inserts made to match each hearing aid for a seamless and reliable recharge. They offer up to 24 hours use-time on a single charge – even when streaming – for worry-free, all-day use without the fear of batteries running out on the go. Users can wear glasses or face masks without worrying about them getting snagged on their hearing aids and take hands-free phone and FaceTime calls on their iPhone or iPad** with the touch of a finger.

The new Custom made by ReSound hearing aids provide natural hearing in any situation by allowing users to hear with their own ears, for greater spatial awareness and a truly personalized sound. They deliver up to 30% better speech understanding in noise and 1-2 dB more directional benefit***. The solution incorporates All-Access Directionality which means the hearing aids automatically adjust to surroundings in real time. This enables the brain to select sounds naturally so that no matter the situation, users can enjoy conversations and sounds without being cut off from their surroundings.

GN Hearing CEO, Gitte Aabo explains, “GN Hearing is challenging conventions and setting the stage for an entirely new standard. This new sleek design will make people think again and encourage them to take care of their hearing health by offering the most advanced hearing aid technology in a design they will love.”

The new Custom made by ReSound hearing aids are planned for Regulatory clearance and rolled out globally starting with the US on June 29, 2022, along with the equivalent Beltone Imagine line-up, in both ITC (In-The-Canal) and ITE (In-the-Ear) styles. The Custom made by ReSound hearing aids offer a great choice of colors and will be available in a new In-styleTM anthracite color or Blend-inTM hair and skin tones.

For more information, visit the ReSound website.

*58% of non-hearing aid users (n=419) use headphones or earbuds to help with their hearing, trying other devices before exploring hearing aids. GN Fidelity End User multi-market study, 2021, internal

**Hands-free calls are compatible with iPhone 11 or later, iPad Pro 12.9-inch (5th generation), iPad Pro 11-inch (3rd generation), iPad Air (4th generation), and iPad mini (6th generation), with software updates iOS 15.3 and iPadOS 15.3 or later.

*** Compared to ReSound LiNX Quattro products, Groth J. (2020). The evolution of the binaural hearing strategy: All Access Directionality and Ultra Focus. ReSound white paper

– ENDS –

NOTES TO EDITORS

About ReSound

ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.

About GN Group

GN Group facilitates communication between people through its intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our innovation leadership, we leverage technological synergies to deliver unique and increasingly individualized user experiences in our products and solutions.

150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, audio, video and speech, wireless technologies, miniaturization, and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, SteelSeries, Jabra, Beltone, Interton, BlueParrott, Danavox and FalCom in around 100 countries. Founded in 1869, the GN Group employs 7,000 people and is listed on Nasdaq Copenhagen (GN.CO). ​

Visit our homepage GN.com and connect with us on LinkedIn and Facebook .

© 2022 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad, and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For further information, please contact:

Press and the media

Marie Schleimann Nordlund
Director of PR and Communication
Tel: +45 31 26 37 34

Lars Otto Andersen-Lange
Head of Media Relations & Corporate Public Affairs
Tel: +45 45 75 02 55

Investors and analysts

Henriette Wennicke
Vice President, Investor Relations & Treasury
Tel: +45 45 75 03 33

Rune Sandager
Director, Investor Relations & Treasury
Tel: +45 45 75 92 57

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p